Lynx1 Capital Management LP Stoke Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $257 Million
- Q4 2024
A detailed history of Lynx1 Capital Management LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,187,191 shares of STOK stock, worth $41.5 Million. This represents 22.22% of its overall portfolio holdings.
Number of Shares
5,187,191
Previous 5,187,191
-0.0%
Holding current value
$41.5 Million
Previous $63.8 Million
10.25%
% of portfolio
22.22%
Previous 22.82%
Shares
5 transactions
Others Institutions Holding STOK
# of Institutions
136Shares Held
57.3MCall Options Held
5.7KPut Options Held
24.4K-
Skorpios Trust6.91MShares$55.3 Million99.8% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$43.3 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$41 Million0.92% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$37.1 Million0.57% of portfolio
-
Redmile Group, LLC San Francisco, CA4.59MShares$36.8 Million3.96% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $316M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...